Skip to Primary Navigation

Regulatory uncertainty brings risk and opportunity to pharma in 2025, says Jeff Lemay

Montage with Jeff Lemay and a wall of prescription drugs.
GRIP Montage: Spencer Platt/Getty Images/Private

CCO Jeff Lemay reflects on his time at Jazz Pharmaceuticals and asseses the road ahead for compliance and legal teams in the pharma sector.

New market and policy initiatives in 2025 create a truly challenging healthcare environment, but they also present businesses and stakeholders with the opportunity to expand into some new areas, such as new technology leveraging artificial intelligence (AI).

Functions are rarely siloed any longer, as teams must collaborate to navigate ever-changing supply

Get full access, free for a month

Start your 28-day free trial to continue reading and access
all content on GRIP – no payment details required.

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience